Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Operating Leases (2019 - 2026)

Cogent Biosciences' Operating Leases history spans 8 years, with the latest figure at $14.1 million for Q1 2026.

  • Quarterly Operating Leases fell 8.93% to $14.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Mar 2026, down 8.93% year-over-year, with the annual reading at $14.4 million for FY2025, 9.73% down from the prior year.
  • Operating Leases came in at $14.1 million for Q1 2026, down from $14.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $19.0 million in Q2 2022 to a low of $1.1 million in Q1 2022.
  • The 5-year median for Operating Leases is $16.7 million (2024), against an average of $15.8 million.
  • The largest YoY upside for Operating Leases was 2093.26% in 2022 against a maximum downside of 56.74% in 2022.
  • Cogent Biosciences' Operating Leases stood at $18.2 million in 2022, then fell by 4.16% to $17.5 million in 2023, then dropped by 8.96% to $15.9 million in 2024, then fell by 9.73% to $14.4 million in 2025, then dropped by 1.8% to $14.1 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Operating Leases are $14.1 million (Q1 2026), $14.4 million (Q4 2025), and $14.6 million (Q3 2025).